Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2016 | Pages:
65 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Cyclin-Dependent Kinase 2 (p33 Protein Kinase or cdc2-Related Protein Kinase or EC 2.7.11.22) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Cyclin-Dependent Kinase 2 (p33 Protein Kinase or cdc2-Related Protein Kinase or EC 2.7.11.22) - Pipeline Review, H1 2016', provides in depth analysis on Cyclin-Dependent Kinase 2 (p33 Protein Kinase or cdc2-Related Protein Kinase or EC 2.7.11.22) targeted pipeline therapeutics. The report provides comprehensive information on the Cyclin-Dependent Kinase 2 (p33 Protein Kinase or cdc2-Related Protein Kinase or EC 2.7.11.22), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cyclin-Dependent Kinase 2 (p33 Protein Kinase or cdc2-Related Protein Kinase or EC 2.7.11.22) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Cyclin-Dependent Kinase 2 (p33 Protein Kinase or cdc2-Related Protein Kinase or EC 2.7.11.22) - The report reviews Cyclin-Dependent Kinase 2 (p33 Protein Kinase or cdc2-Related Protein Kinase or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Cyclin-Dependent Kinase 2 (p33 Protein Kinase or cdc2-Related Protein Kinase or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects - The report assesses Cyclin-Dependent Kinase 2 (p33 Protein Kinase or cdc2-Related Protein Kinase or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Cyclin-Dependent Kinase 2 (p33 Protein Kinase or cdc2-Related Protein Kinase or EC 2.7.11.22) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Cyclin-Dependent Kinase 2 (p33 Protein Kinase or cdc2-Related Protein Kinase or EC 2.7.11.22) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Cyclin-Dependent Kinase 2 (p33 Protein Kinase or cdc2-Related Protein Kinase or EC 2.7.11.22) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Cyclin-Dependent Kinase 2 (p33 Protein Kinase or cdc2-Related Protein Kinase or EC 2.7.11.22) Overview 7 Therapeutics Development 8 Cyclin-Dependent Kinase 2 (p33 Protein Kinase or cdc2-Related Protein Kinase or EC 2.7.11.22) - Products under Development by Stage of Development 8 Cyclin-Dependent Kinase 2 (p33 Protein Kinase or cdc2-Related Protein Kinase or EC 2.7.11.22) - Products under Development by Therapy Area 9 Cyclin-Dependent Kinase 2 (p33 Protein Kinase or cdc2-Related Protein Kinase or EC 2.7.11.22) - Products under Development by Indication 10 Cyclin-Dependent Kinase 2 (p33 Protein Kinase or cdc2-Related Protein Kinase or EC 2.7.11.22) - Pipeline Products Glance 12 Late Stage Products 12 Early Stage Products 13 Cyclin-Dependent Kinase 2 (p33 Protein Kinase or cdc2-Related Protein Kinase or EC 2.7.11.22) - Products under Development by Companies 14 Cyclin-Dependent Kinase 2 (p33 Protein Kinase or cdc2-Related Protein Kinase or EC 2.7.11.22) - Products under Development by Universities/Institutes 17 Cyclin-Dependent Kinase 2 (p33 Protein Kinase or cdc2-Related Protein Kinase or EC 2.7.11.22) - Therapeutics Assessment 19 Assessment by Monotherapy/Combination Products 19 Assessment by Mechanism of Action 20 Assessment by Route of Administration 21 Assessment by Molecule Type 23 Cyclin-Dependent Kinase 2 (p33 Protein Kinase or cdc2-Related Protein Kinase or EC 2.7.11.22) - Companies Involved in Therapeutics Development 24 Astex Pharmaceuticals, Inc. 24 Cyclacel Pharmaceuticals, Inc. 25 Tiziana Life Sciences Plc 26 Tragara Pharmaceuticals, Inc. 27 Cyclin-Dependent Kinase 2 (p33 Protein Kinase or cdc2-Related Protein Kinase or EC 2.7.11.22) - Drug Profiles 28 AT-7519 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 CCT-68127 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 CYC-065 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 JRP-890 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 milciclib - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 sapacitabine + seliciclib - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 seliciclib - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 Small Molecule to Inhibit CDK2 for Oncology - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 Small Molecules to Inhibit CDK2 for Oncology - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 TG-02 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 Cyclin-Dependent Kinase 2 (p33 Protein Kinase or cdc2-Related Protein Kinase or EC 2.7.11.22) - Dormant Projects 48 Cyclin-Dependent Kinase 2 (p33 Protein Kinase or cdc2-Related Protein Kinase or EC 2.7.11.22) - Discontinued Products 50 Cyclin-Dependent Kinase 2 (p33 Protein Kinase or cdc2-Related Protein Kinase or EC 2.7.11.22) - Featured News & Press Releases 51 Jun 06, 2016: Cyclacel Reports Updated Data From Its DNA Damage Response Program on Seliciclib and Sapacitabine Combination in Patients With Solid Tumors at ASCO 51 May 19, 2016: Cyclacel's Seliciclib-Sapacitabine Abstract Selected for Oral Presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting 53 Apr 18, 2016: Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, is an Effective Inducer of Cell Death in B-cell Lymphoma and Synergizes With Bcl-2 or BET Inhibitors 53 Dec 14, 2015: Molecular Basis for Development of Cyclacel's CYC065 CDK2/9 Inhibitor in Triple-Negative Breast Cancer Presented at San Antonio Breast Cancer Symposium 54 Nov 23, 2015: CYC065, Cyclacel's Novel CDK2/9 Inhibitor, Prolongs Survival in MYCN-Addicted Neuroblastoma Models 55 Nov 09, 2015: Mechanistic Rationale for CYC065, Cyclacel's CDK2/9 Inhibitor, in Targeted Solid Tumors and Hematological Malignancies Presented at AACR-NCI-EORTC International Conference 56 Oct 26, 2015: Data to be Presented on CYC065, Cyclacel's CDK2/9 Inhibitor, at AACR-NCI-EORTC International Conference 57 Oct 22, 2015: Cyclacel Doses First Patient in Phase 1 Trial of Its Novel CDK2/9 Inhibitor, CYC065, for the Treatment of Advanced Solid Tumors 57 Sep 17, 2015: Cyclacel Presents Molecular Rationale for Clinical Development of CYC065 CDK Inhibitor in Leukemias and Lymphomas 58 Jul 02, 2015: First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing's Disease, a Serious Endocrine Disorder 59 Apr 20, 2015: Cyclacel's CDK2/9 Inhibitor, Seliciclib, Preclinical Data Presented at the AACR 59 Apr 20, 2015: Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Demonstrates Therapeutic Potential and Synergy With Other Anti-Cancer Compounds 60 Mar 20, 2015: Cyclacel's CYC065 Featured in Presentations at the American Association for Cancer Research Annual Meeting 2015 61 Oct 28, 2014: Thymic carcinoma Phase II data of Milciclib, a kinase inhibitor discovered at Nerviano Medical Sciences, disclosed at the medical oncology meeting AIOM 2014 62 Sep 18, 2014: Cyclacel's CYC065 CDK Inhibitor Demonstrates Therapeutic Potential in Acute Leukemias With Mixed Lineage Leukemia (MLL) Rearrangements 62 Appendix 64 Methodology 64 Coverage 64 Secondary Research 64 Primary Research 64 Expert Panel Validation 64 Contact Us 64 Disclaimer 65
List of Tables
Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Indication, H1 2016 10 Comparative Analysis by Late Stage Development, H1 2016 12 Comparative Analysis by Early Stage Products, H1 2016 13 Number of Products under Development by Companies, H1 2016 14 Products under Development by Companies, H1 2016 15 Products under Development by Companies, H1 2016 (Contd..1) 16 Number of Products under Investigation by Universities/Institutes, H1 2016 17 Products under Investigation by Universities/Institutes, H1 2016 18 Assessment by Monotherapy/Combination Products, H1 2016 19 Number of Products by Stage and Mechanism of Action, H1 2016 20 Number of Products by Stage and Route of Administration, H1 2016 22 Number of Products by Stage and Molecule Type, H1 2016 23 Pipeline by Astex Pharmaceuticals, Inc., H1 2016 24 Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016 25 Pipeline by Tiziana Life Sciences Plc, H1 2016 26 Pipeline by Tragara Pharmaceuticals, Inc., H1 2016 27 Dormant Projects, H1 2016 48 Dormant Projects (Contd..1), H1 2016 49 Discontinued Products, H1 2016 50
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
